Pre-clinical Vaccine and Antibody Development for Coronavirus Disease 2019 (COVID-19)

Document text

Principal Investigator: Richard A Koup
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $285,362
Funding agency: National Institute of Allergy and Infectious Diseases

Since there is no effective cure for COVID-19. Though the mRNA vaccines were authorized for emergency use, the durability of protection provided by these two mRNA vaccines is still a concern, given the fact that the spike-specific antibodies decline rapidly in convalescent sera of COVID patients. During the past years, the Virology Laboratory has collaborated with other intramural NIAID labs and other external collaborators to develop a more effective and long-lasting vaccine for controlling the ongoing pandemic and for preventing future outbreaks. 

For the past last year, we are testing various new designs of non-infectious self-assembly Virus-Like-Particle (VLP) expressing the SARS-CoV-2 spike on the nanoparticles' surface as a potential improved vaccine which may elicit stronger and prolong immune responses. We are testing two concepts, first one is to see if we can express and produce VLPs with target antigens on the VLP surface, the second one is to use gene-base vaccine approach for delivering the modified VLP gene directly in order to avoid the common problems involving the production of the modified VLPs immunogens. We first assessed whether hepatitis B surface antigen (HBsAg)-based nanoparticles and also lumazine synthase nanoparticles with SARS-CoV-2 spike can elicit potent and long lasting immunity against SARS-CoV-2 in mice . The data showed that genetic delivery of SARS-CoV-2 S6P-HBsAg and also on lumazine synthase nanoparticles can both elicit potent and durable neutralizing antibody (nAb) responses. S6P-HBsAgs can elicit substantially more potent nAb responses than S2P matching mRNA-1273 in mice. Our findings highlight the potential of S6P-HBsAgs as next generation genetic vaccine candidates against SARS-CoV-2. Furthermore, we are testing antigen protein mucosal boosting after the initial gene-based prime immunization would elicit improved immune responses or not.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Antibodies><Antibody Response><Antigen Targeting><Antigens><Au antigen><Australia Antigen><COVID infected patient><COVID patient><COVID positive patient><COVID-19><COVID-19 immunity><COVID-19 infected patient><COVID-19 infection><COVID-19 patient><COVID-19 positive patient><COVID-19 virus><COVID19><COVID19 immunity><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><CV19><CoV-2><CoV2><Data><Development><Disease Outbreaks><Emergencies><Emergency Situation><Future><Genes><Genetic><HBsAg><HBsAg (hepatitis B surface antigen)><Hepatitis B Surface Antigens><Human><Immune response><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><Laboratories><Mice><Mice Mammals><Modern Man><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Mucosa><Mucosal Tissue><Mucous Membrane><Murine><Mus><NIAID><National Institute of Allergy and Infectious Disease><Outbreaks><Production><Proteins><RNA vaccine><RNA-based vaccine><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 immunity><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Surface><Testing><Vaccinee><Vaccines><Virus-like particle><Wuhan coronavirus><antigen based test><antigen test><base><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 immunity><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 patient><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><design><designing><developmental><genetic vaccine><hCoV19><hepatitis associated antigen><host response><immune system response><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunogen><immunoresponse><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><lumazine><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><nCoV2><nano particle><nano-sized particle><nanoparticle><nanosized particle><neutralizing antibody><next generation><pandemic><pandemic disease><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pre-clinical><preclinical><prevent><preventing><self assembly><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccine antibodies><vaccine candidate><vaccine induced antibodies><vaccine-induced antibodies><virology><virus-like nanoparticles><viruslike particle>